KRT7 and renal cell carcinoma: By comparison, the immunoreactivity in MTSCC-K was as follows: AMACR, 93%; CK7, 81%; EMA, 95%; RCC Ma, 7%; CD10, 15%; HMWK, 15%; and c-kit, 5%.